You are here: Home » Companies » Financial X-Ray
TaMo to invest Rs 28,900 cr in domestic biz, JLR in FY22: Chandrasekaran
Business Standard

Sun Pharma: Strong Q1 show, settlement of antitrust case pleases investors

Lack of pricing pressure, especially in the US, and debt reduction are other positives

Topics
Sun Pharma | Investors | Q1 results

Devangshu Datta  |  New Delhi 



Sun Pharma
Sun Pharma is the largest player in India’s pharma market, with about 8 per cent market share

A strong Q1, 2021-22 (Apr-Jun 2021) performance saw the share price of jump by 10 per cent in a single session. The pharma major had terrific year-on-year (YoY) results, boosted by the low base of Q1, 2020-21. But it also had a pretty good quarter-on-quarter (QoQ) performance versus Jan-Mar 2021 (Q4, 2020-21).

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Fri, July 30 2021. 20:27 IST

RECOMMENDED FOR YOU

.